Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.0384 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.0384 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.0384 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.0384 | 1 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 0.0384 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.0114 | 0.5189 | 0.4997 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.0384 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.0384 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.0384 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.0384 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 0.0384 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.0384 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 0.0384 | 0.5 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0114 | 0.5189 | 0.4997 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.0384 | 1 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0106 | 0.4763 | 0.4554 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 0.5 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 0.0384 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0.0384 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.0384 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.0384 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.0384 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 1 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.0384 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 0.0384 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.0384 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.3663 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.4125 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 3.6964 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 37.933 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.